These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8957265)

  • 1. Evidence for alcohol anti-craving properties of memantine.
    Hölter SM; Danysz W; Spanagel R
    Eur J Pharmacol; 1996 Oct; 314(3):R1-2. PubMed ID: 8957265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot double-blind treatment trial of memantine for alcohol dependence.
    Evans SM; Levin FR; Brooks DJ; Garawi F
    Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine.
    Piasecki J; Koros E; Dyr W; Kostowski W; Danysz W; Bienkowski P
    Eur J Pharmacol; 1998 Aug; 354(2-3):135-43. PubMed ID: 9754913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of memantine in combination with alcohol in moderate drinkers.
    Bisaga A; Evans SM
    Psychopharmacology (Berl); 2004 Feb; 172(1):16-24. PubMed ID: 14530901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the non-competitive NMDA receptor antagonist memantine on the volitional consumption of ethanol by alcohol-preferring rats.
    Malpass GE; Williams HL; McMillen BA
    Basic Clin Pharmacol Toxicol; 2010 May; 106(5):435-44. PubMed ID: 20210793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients.
    Krupitsky EM; Neznanova O; Masalov D; Burakov AM; Didenko T; Romanova T; Tsoy M; Bespalov A; Slavina TY; Grinenko AA; Petrakis IL; Pittman B; Gueorguieva R; Zvartau EE; Krystal JH
    Am J Psychiatry; 2007 Mar; 164(3):519-23. PubMed ID: 17329479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMDA antagonists inhibit the development of ethanol dependence in rats.
    Kotlińska J
    Pol J Pharmacol; 2001; 53(1):47-50. PubMed ID: 11785910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine: a new approach to Alzheimer's disease.
    Keltner NL; Williams B
    Perspect Psychiatr Care; 2004; 40(3):123-4. PubMed ID: 15515294
    [No Abstract]   [Full Text] [Related]  

  • 9. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases.
    Monastero R; Camarda C; Pipia C; Camarda R
    J Neurol Neurosurg Psychiatry; 2007 May; 78(5):546. PubMed ID: 17030587
    [No Abstract]   [Full Text] [Related]  

  • 10. Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
    Kikuchi T
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32751985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's congress. Drug shows promise for advanced disease.
    Marx J
    Science; 2000 Jul; 289(5478):375-7. PubMed ID: 10939942
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.
    Parsons CG; Danysz W; Quack G
    Neuropharmacology; 1999 Jun; 38(6):735-67. PubMed ID: 10465680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
    Zakharova E; Malyshkin A; Kashkin V; Neznanova O; Sukhotina I; Danysz W; Bespalov A
    Behav Pharmacol; 2004 Jul; 15(4):273-8. PubMed ID: 15252277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Memantine: from the original brand to generics].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic possibilities with low-affinity NMDA receptor antagonists].
    Kornhuber J; Weller M
    Nervenarzt; 1996 Jan; 67(1):77-82. PubMed ID: 8676993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam.
    Krupitsky EM; Rudenko AA; Burakov AM; Slavina TY; Grinenko AA; Pittman B; Gueorguieva R; Petrakis IL; Zvartau EE; Krystal JH
    Alcohol Clin Exp Res; 2007 Apr; 31(4):604-11. PubMed ID: 17374039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of memantine for elderly patients in the mild stage of Alzheimer's and vascular dementia].
    Bachyns'ka NIu; Rozheliuk IF; Polietaieva KM; Kholin VO
    Lik Sprava; 2013; (7):80-96. PubMed ID: 25509921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Memantine and Complex Regional Pain Syndrome (CRPS): effects of treatment and cortical reorganisation].
    Sinis N; Birbaumer N; Schwarz A; Gustin S; Unertl K; Schaller HE; Haerle M
    Handchir Mikrochir Plast Chir; 2006 Jun; 38(3):164-71. PubMed ID: 16883501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain.
    Wiech K; Kiefer RT; Töpfner S; Preissl H; Braun C; Unertl K; Flor H; Birbaumer N
    Anesth Analg; 2004 Feb; 98(2):408-413. PubMed ID: 14742379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.